FTE Support. The collaboration will, on an annual average basis, consist of **** FTEs. BOEHRINGER shall allocate an annual average of **** FTEs to the collaborative Research Programme and EVOTEC shall supply an annual average of **** FTEs to the Research Programme to be paid by BOEHRINGER at the rate per FIE specified under Section 8.01, which funding shall be fully made through payments under Section 8.01 and 8.02 without further claim for compensation from EVOTEC with respect thereto. If reasonably necessary, the FTE resources may be adjusted, subject to the approval of the Research Executive Committee. In the event the Research Executive Committee should approve additional EVOTEC FTE resources, then BOEHRINGER shall compensate EVOTEC on an annual FTE rate equal to **** or by an equivalent BOEHRINGER contribution to the conduct of the Research Programme. The alternative chosen has to be mutually agreed between the Parties in the Executive Committee and the final say of BOEHRINGER under Section 3.04 shall not apply.
FTE Support. The minimum Staffing Level to be provided by MORPHOSYS shall be [***], for MORPHOSYS to prepare a Collaboration Plan and to perform the activities under such Collaboration Plan. ONCOMED agrees to fund the minimum Staffing Level determined under this Section 3.2(b). ONCOMED and MORPHOSYS both acknowledge that the actual Staffing Level to be devoted by MORPHOSYS, and funded by ONCOMED, for any project under the Collaboration may be, as estimated in good faith by MORPHOSYS, higher than the aforementioned minimum number. In such case, the actual Staffing Level for each Collaboration project shall be mutually agreed upon by the Parties. Notwithstanding the foregoing, if MORPHOSYS determines in good faith that the minimum Staffing Level required to carry out a project under the Collaboration would be less than the number referred to in this Section 3.2(b), MORPHOSYS will notify ONCOMED accordingly, in which case the minimum Staffing Level will be reduced accordingly, and ONCOMED shall only pay for those FTEs that are devoted to such Collaboration project.
FTE Support. At any time during the First Contract Year, Roche shall not be required to provide funding for more than [**] FTEs for all Research Projects. At any time during the Second Contract Year, Roche shall not be required to provide funding for more than [CONFIDENTIAL TREATMENT REQUESTED] FTEs for all Research Projects. At any time during the remaining three (3) Contract Years: (i) if Roche elects to continue the restrictions contained in Section 5.12 in their entirety pursuant to Section 5.12(d), then Roche shall be required to provide funding for at least [CONFIDENTIAL TREATMENT REQUESTED] FTEs for all Research Projects; (ii) if Roche elects not to continue the restrictions contained in Section 5.11 pursuant to Section 5.12(d), then Roche shall be required to provide funding for no more than [CONFIDENTIAL TREATMENT REQUESTED] FTEs for all Research Projects.
FTE Support. 16 9.1.1 In Vitro Target Validation Studies............................16 9.1.2 In Vivo Target Validation Studies.............................17 9.1.3 Payment.......................................................17 9.2
FTE Support. The Parties mutually agree that, as of the Amendment Date, no changes to the FTE set forth in Section 5.2 and Exhibit E of the Collaboration and License Agreement are required due to the licensing, transfer and implementation of the XxXX Technology and its integration under the Collaboration under the Collaboration and License Agreement.
FTE Support. At any time during the Research Term, Roche shall not be required to provide funding for more than [CONFIDENTIAL TREATMENT REQUESTED] per contract year for all Major Research Programs. At any time during the Research Term, Roche shall not be required to provide funding for more than [CONFIDENTIAL TREATMENT REQUESTED] per contract year for all Minor Research Programs.
FTE Support. The number of BG and GPC FTEs devoted by each Party to the transfer of the GPC Platform and the Collaboration shall be as set forth on the Resource Plan as described in Exhibit E attached hereto. Subject to BG’s obligations under the Research Plan, BG’s FTEs not included in the Resource Plan working at the Genomics Center may be reasonably assigned by the BG management team at the Genomics Center to other research programs to be performed and technologies to be applied by BG which do not relate to the Collaboration or incorporate other technologies of the GPC Platform. In addition, subject to the consent of the Joint Steering Committee, BG FTEs included in the Resource Plan may also be subject to reasonable assignment to other programs being conducted at the Genomics Center, provided that the time schedules and the achievement of the milestones set forth in the Research Plan, to the extent dependent on the efforts of BG FTEs, and the transfer of the GPC Platform are not, in the opinion of the Joint Steering Committee, negatively affected.
FTE Support. GPC shall provide the following FTEs for transfer of the GPC Yeast 3-Hybrid Technology and the Collaboration. Until December 31, 2004: *** FTEs; during 2005, *** FTEs; during 2006 , *** FTE, and from January 1, 2007 through June 30, 2007, *** FTE. The Joint Steering Committee shall allocate the FTEs depending on the progress and needs of the Collaboration.
FTE Support. In support of research and development to be conducted by Millennium pursuant to this Agreement, Astra will make the following payments to Millennium:
(i) To fund the Millennium Research Program, Astra shall pay to Millennium an amount equal to the following amounts per FTE: The full-time equivalent rate shall be [**] per FTE (all inclusive) from the Effective Date to December 31, 1996 (the "FTE Rate"). On each January 1 thereafter, the FTE Rate shall be adjusted by an amount equal to the percentage increase or decrease, if any, in the United States Consumer Price Index (or any comparable successor index thereto) from the immediately preceding January 1.
(ii) During the first three (3) Contract Years, Millennium shall provide, and Astra shall fund, a minimum (but not more than the number of FTEs actually provided by Millennium) of [**] FTEs for the first Contract Year; [**] FTEs for the second Contract Year; and [**] FTEs for the third Contract Year; it being understood that the number of FTEs actually working on the Millennium Research Program in the first Contract Year will gradually increase as FTEs are hired. Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
(iii) In accordance with Astra's election, pursuant to Section 2.7(b) and 2.7(c), to extend the term of the Millennium Research Program until the end of the seventh Contract Year, Millennium shall provide, and Astra shall fund, during the fourth through seventh Contract Years, a minimum (but Astra shall not fund more than the number of FTEs actually provided by Millennium) of [**] FTEs for the fourth Contract Year, [**] FTEs for the fifth Contract Year, [**] FTEs for the sixth Contract Year, and [**] for the seventh Contract Year.
(iv) The numbers set forth above for FTE employees to be provided by Millennium, and funded by Astra, for research and development from the Effective Date through the end of the Millennium Research Program may be adjusted from time to time by decision of the Joint Management Team, PROVIDED, HOWEVER, that the number of FTEs funded by Astra shall not be below the minimums set forth above, except by mutual agreement of the Parties.
(v) Within ten (10) days of the first day of each contract quarter, Astra shall pay to Millennium the total amount due for the upcoming quarter. Within thirty (30) days of the completion of each contract quarter, Millennium shall provide Astra with a written statement setti...
FTE Support. As consideration for Evotec providing the FTE support set out in Section 3.5 and as further specified in the Research Plan, Novo shall pay an amount of [***] per calendar year per FTE working on the Collaboration, without further claim for compensation from Evotec with respect thereto. Evotec shall invoice the FTE activities in advance on a Calendar Quarter basis and shall adjust to actuals retroactively in the next Calendar Quarter. If reasonably necessary, the FTE resources may be adjusted, subject to the approval of the JSC. EXECUTION VERSION 8 July 2020
